Quantcast
Last updated on April 20, 2014 at 1:20 EDT

Latest Oncology Stories

2014-04-08 08:31:34

SUNNYVALE, Calif., April 8, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATE(TM) study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICA(TM) (ibrutinib) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who...

2014-04-08 08:30:19

SAN DIEGO, April 8, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation. "Initiation of...

2014-04-08 08:30:17

Patent provides protection until 2033 and complements Epizyme's issued composition of matter claims for EZH2 inhibitors CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients...

2014-04-08 00:21:50

Fox Family Cancer Research Funding Trust Is Contributing to Support Team SAN DIEGO, April 7, 2014 /PRNewswire-USNewswire/ -- Stand Up To Cancer (SU2C), The Lustgarten Foundation, and the Fox Family Cancer Research Funding Trust, along with the American Association for Cancer Research (AACR), SU2C's Scientific Partner, announced the formation of a Dream Team dedicated to pancreatic cancer research during a press event today at the AACR Annual Meeting 2014, held here April 5-9. Elizabeth M....

2014-04-07 16:05:15

Researchers studying a rare, always fatal brain tumor in children have found several molecular alterations that drive the cancer, according to a new study from scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and McGill University. The findings identify potential new targets for drug treatments. The new research could help physicians choose targeted agents with a better chance of combating pediatric high-grade astrocytomas, which are extremely difficult to...

2014-04-07 15:48:32

A University of Colorado Cancer Center study recently published in the journal Cell Reports and presented today at the American Association for Cancer Research (AACR) Annual Conference 2014 shows that the cellular process of autophagy in which cells "eat" parts of themselves in times of stress may allow cancer cells to recover and divide rather than die when faced with chemotherapies. Autophagy, from the Greek "to eat oneself," is a process of cellular recycling in which cell organelles...

2014-04-07 12:50:07

A University of Colorado Cancer Center study published today in Journal of the National Cancer Institute (with related research being presented this weekend at the American Association for Cancer Research Annual Conference 2014) details the discovery of a new genetic driver of bladder cancer: silencing of the gene AGL. "We tend to think of cancer resulting from mutations that let genes make things they shouldn't or turn on when they should be quiet. But cancer can also result from loss of...

2014-04-07 12:47:39

A new genetic "signature" to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna will hear today (Saturday). Professor Robert Bristow will tell the conference that although surgery and precision radiotherapy are the mainstays of treatment for cancer that is confined to the prostate, the cancer...

2014-04-07 12:33:35

The Most Promising Emerging Agents in Development for Triple Negative Breast Cancer Target Only Specific Patient Subsets, According to Findings from Decision Resources Group BURLINGTON, Mass., April 7, 2014 /PRNewswire/ -- Decision Resources Group finds that due to the heterogeneity of triple negative breast cancer the most promising emerging agents in development, target only specific subsets of patients. The two novel emerging therapies niraparib (Tesaro) and Xtandi (Medivation/Astellas)...

2014-04-07 08:31:31

ALBANY, New York, April 7, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Breast Imaging Market(Mammography, Breast MRI, Breast Ultrasound, Tomosynthesis, Nuclear Imaging and Others [Breast Thermography & Bioelectric Imaging])- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", the global breast imagingmarket was valued at USD 1.84 billionin 2012 and is expected to grow at a CAGR of 12% from...